Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 84

Sort by

Sort Order Select

Journal Articles

Resensitizing the Imatinib-Resistant Chronic Myeloid Leukemia through Reshaping the Glucose Mtabolism By Insulin Sensitizer

Qian LAI, Hongpeng Duan, Yuelong Jiang, Liuzhen Yang, Manman Deng, Zhijuan Lin, Weihang Shan, Mengya Zhong, Jingwei Yao, Li Zhang, Jie Zha, Bing Xu

Blood (2024) 144 (Supplement 1): 5781.

https://doi.org/10.1182/blood-2024-208054

Published: 2024

Journal Articles

A China Survey on the Insights of Patients Living with Follicular Lymphoma: The Real-World Patient Journey Analysis

Yang He, Huilai Zhang, Bing Xu, Zengjun Li, Zheng Song, Qiuhui Jiang, Hui Wang, Weili Zhao

Blood (2024) 144 (Supplement 1): 7622.

https://doi.org/10.1182/blood-2024-206977

Published: 2024

Journal Articles

Spatial Architecture of Immune Microenvironment Orchestrating Anti-Lymphoma Immunity and the Response to Immunochemotherapy in EBV+ Diffused Large B Cell Lymphoma Revealed By Imaging Mass Cytometry and Spatial Transcriptome

Zhijuan Lin, Xingxing Yu, Yan Hong, Long Liu, Zhifeng Li, Jie Zha, Bing Xu

Blood (2024) 144 (Supplement 1): 452.

https://doi.org/10.1182/blood-2024-210210

Published: 2024

Journal Articles

Suvmax Linked to Intrafollicular Macrophage Infiltration Is Associated with Poor Outcome of Follicular Lymphoma

Zhijuan Lin, Xingxing Yu, Yan Hong, Long Liu, Jie Zha, Bing Xu

Blood (2024) 144 (Supplement 1): 4379.

https://doi.org/10.1182/blood-2024-205432

Published: 2024

Journal Articles

CD163+ Macrophages Orchestrate Tumor Immunity By Spatially Fortifying Follicular Lymphoma Against CD8+ T Cells Attack during Early Progression

Zhijuan Lin, Xingxing Yu, Yan Hong, Long Liu, Zhifeng Li, Jie Zha, Bing Xu

Blood (2024) 144 (Supplement 1): 1621.

https://doi.org/10.1182/blood-2024-207677

Published: 2024

Journal Articles

Neuronal-Glial and Immune Microenvironment Signatures Show Prognostic Effects in Primary CNS Lymphoma

Blood (2024) 144 (Supplement 1): 4361.

https://doi.org/10.1182/blood-2024-201598

Published: 2024

Journal Articles

Diffuse Large B-Cell Lymphoma Has a Low Frequency of dMMR and High Frequencies of DNA Mismatch Repair Protein High Expression Associated with Lower T-Cell Infiltration

Blood (2023) 142 (Supplement 1): 6079.

https://doi.org/10.1182/blood-2023-178366

Published: 2023

Journal Articles

Development and Validation of a Machine-Learning Model to Predict POD24 Risk of Follicular Lymphoma

Blood (2023) 142 (Supplement 1): 3048.

https://doi.org/10.1182/blood-2023-182812

Published: 2023

Journal Articles

Orelabrutinib Monotherapy in Patients with Relapsed or Refractory Waldenström's Macroglobulinemia in a Single-Arm, Multicenter, Open-Label, Phase 2 Study: Long Term Follow-up Results

Blood (2023) 142 (Supplement 1): 3039.

https://doi.org/10.1182/blood-2023-181500

Published: 2023

Journal Articles

Update Results of a Phase II Trial of Venetoclax in Combination with Azacitidine and Chidamide in Relapsed/Refractory Acute Myeloid Leukemia

Blood (2023) 142 (Supplement 1): 4274.

https://doi.org/10.1182/blood-2023-182832

Published: 2023

Journal Articles

Tumor-Infiltrating Normal B Lymphocytes Have Remarkable Prognostic Effects and Are Crucial for Antitumor Immune Responses in Diffuse Large B-Cell Lymphoma

Blood (2023) 142 (Supplement 1): 429.

https://doi.org/10.1182/blood-2023-179972

Published: 2023

Journal Articles

Time to Lymphoma Treatment within 24 Months in Watchful Waiting Follicular Lymphoma Defines Patients at High Risk for Progression: A Multicenter Analysis

Fenghua Gao, Jing Liu, Jiesong Wang, Lihong Liu, Zhiming Li, Yuqin Song, Xudong Zhang, Hui Zhou, Xiuhua Sun, Wei Zhang, Bing Xu, Liping Su, Wen Shujuan, Rong Tao, Ou Bai, Qingyuan Zhang, Liqun Zou, Xianhuo Wang, Huilai Zhang

Blood (2023) 142 (Supplement 1): 4417.

https://doi.org/10.1182/blood-2023-174308

Published: 2023

Journal Articles

Identification of Hub Genes and Pathways Associated with Follicular Lymphoma (FL) Via Bioinformatics Analysis

Yirong Jiang, Jingwei Yao, Mengya Zhong, Zhuoxin Yao, Zhangkun Li, Ziying Fan, Jie Zha, Bing Xu

Blood (2022) 140 (Supplement 1): 11959.

https://doi.org/10.1182/blood-2022-165258

Published: 2022

Journal Articles

Preclinical Studies and Phase II Trial of Venetoclax in Combination with Chidamide and Azacitidine in Relapsed/Refractory Acute Myeloid Leukemia

Blood (2022) 140 (Supplement 1): 3292–3293.

https://doi.org/10.1182/blood-2022-165261

Published: 2022

Journal Articles

Clinical Characteristics and Outcomes of Follicular Lymphoma Patients with Extranodal Involvement: Analysis of a Series of 1090 Cases in China

Blood (2022) 140 (Supplement 1): 11979–11980.

https://doi.org/10.1182/blood-2022-162488

Published: 2022

Journal Articles

Preclinical Studies of Chiauranib Inhibit Follicular Lymphoma through VEGFR2/ERK/STAT3 Signaling Pathway

Yuanfang Tang, Mengya Zhong, Jie Zha, Bing Xu

Blood (2022) 140 (Supplement 1): 11578.

https://doi.org/10.1182/blood-2022-162456

Published: 2022

Journal Articles

Orelabrutinib and Venetoclax Show Synergistic Lethality in Double-Hit Lymphoma By Interfering with the Crosstalk between the PI3K/AKT and p38/MAPK Signaling

Mengya Zhong, Guangchao Pan, Jie Zha, Bing Xu

Blood (2022) 140 (Supplement 1): 11566–11567.

https://doi.org/10.1182/blood-2022-159944

Published: 2022

Journal Articles

NPM1 Mutation Reprograms Leukemic Transcription Network Via Reshaping CTCF-Defined TAD Topology

Karina Hamamoto, Qian Lai, Huacheng Luo, Julia Lesperance, Zachary Zaroogian, Jie Zha, Yi Qiu, Olga A Guryanova, Bing Xu, Suming Huang

Blood (2022) 140 (Supplement 1): 722–723.

https://doi.org/10.1182/blood-2022-160367

Published: 2022

Journal Articles

Novel Therapeutic Combining CS055 with Chiglitazar Targets Leukemia Stem and Progenitor Cells in Acute Myeloid Leukemia

Hui Zhou, Dongmei Qin, Chendi Xie, Jie Zhou, Wenjuan Li, Mengya Zhong, Yuelong Jiang, Manman Deng, Haijun Zhao, Yong Zhou, Qian Lai, Zhihong Fang, Yiming Luo, Bing Xu, Jie Zha

Blood (2022) 140 (Supplement 1): 11731.

https://doi.org/10.1182/blood-2022-166807

Published: 2022

Journal Articles

RARγ activation sensitizes human myeloma cells to carfilzomib treatment through the OAS-RNase L innate immune pathway

Qiang Wang, Zhijuan Lin, Zhuo Wang, Lingqun Ye, Miao Xian, Liuling Xiao, Pan Su, Enguang Bi, Yung-hsing Huang, Jianfei Qian, Lintao Liu, Xingzhe Ma, Maojie Yang, Wei Xiong, Youli Zu, Sai Ravi Pingali, Bing Xu, Qing Yi

Blood (2022) 139 (1): 59–72.

https://doi.org/10.1182/blood.2020009856

Published: 2022

Includes: Supplemental data

NARROW

Resensitizing the Imatinib-Resistant Chronic Myeloid Leukemia through Reshaping the Glucose Mtabolism By Insulin Sensitizer

A China Survey on the Insights of Patients Living with Follicular Lymphoma: The Real-World Patient Journey Analysis

Spatial Architecture of Immune Microenvironment Orchestrating Anti-Lymphoma Immunity and the Response to Immunochemotherapy in EBV+ Diffused Large B Cell Lymphoma Revealed By Imaging Mass Cytometry and Spatial Transcriptome

Suvmax Linked to Intrafollicular Macrophage Infiltration Is Associated with Poor Outcome of Follicular Lymphoma

CD163+ Macrophages Orchestrate Tumor Immunity By Spatially Fortifying Follicular Lymphoma Against CD8+ T Cells Attack during Early Progression

Neuronal-Glial and Immune Microenvironment Signatures Show Prognostic Effects in Primary CNS Lymphoma

Diffuse Large B-Cell Lymphoma Has a Low Frequency of dMMR and High Frequencies of DNA Mismatch Repair Protein High Expression Associated with Lower T-Cell Infiltration

Development and Validation of a Machine-Learning Model to Predict POD24 Risk of Follicular Lymphoma

Orelabrutinib Monotherapy in Patients with Relapsed or Refractory Waldenström's Macroglobulinemia in a Single-Arm, Multicenter, Open-Label, Phase 2 Study: Long Term Follow-up Results

Update Results of a Phase II Trial of Venetoclax in Combination with Azacitidine and Chidamide in Relapsed/Refractory Acute Myeloid Leukemia

Tumor-Infiltrating Normal B Lymphocytes Have Remarkable Prognostic Effects and Are Crucial for Antitumor Immune Responses in Diffuse Large B-Cell Lymphoma

Time to Lymphoma Treatment within 24 Months in Watchful Waiting Follicular Lymphoma Defines Patients at High Risk for Progression: A Multicenter Analysis

Identification of Hub Genes and Pathways Associated with Follicular Lymphoma (FL) Via Bioinformatics Analysis

Preclinical Studies and Phase II Trial of Venetoclax in Combination with Chidamide and Azacitidine in Relapsed/Refractory Acute Myeloid Leukemia

Clinical Characteristics and Outcomes of Follicular Lymphoma Patients with Extranodal Involvement: Analysis of a Series of 1090 Cases in China

Preclinical Studies of Chiauranib Inhibit Follicular Lymphoma through VEGFR2/ERK/STAT3 Signaling Pathway

Orelabrutinib and Venetoclax Show Synergistic Lethality in Double-Hit Lymphoma By Interfering with the Crosstalk between the PI3K/AKT and p38/MAPK Signaling

NPM1 Mutation Reprograms Leukemic Transcription Network Via Reshaping CTCF-Defined TAD Topology

Novel Therapeutic Combining CS055 with Chiglitazar Targets Leukemia Stem and Progenitor Cells in Acute Myeloid Leukemia

RARγ activation sensitizes human myeloma cells to carfilzomib treatment through the OAS-RNase L innate immune pathway

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only